Chugai started phase III clinical trial of Actemra for COVID-19 pneumonia in Japan
On Apr. 8, 2020, Chugai Pharma announced that it is working to start a phase III clinical trial…
Arizona COVID-19 Genomics Union to track the virus
On Apr. 8, 2020, TGen, an affiliate of City of Hope, The Pathogen and Microbiome Institute at Northern…
Gilead announced $20 million philanthropic fund to support nonprofit organizations impacted by the COVID-19 crisis
On Apr. 8, 2020, Gilead Sciences announced the creation of the global Gilead CARES (COVID-19 Acute Relief and…
Biotechnology | COVID-19 | FDA | Therapeutics
Karyopharm to evaluate low dose Selinexor as potential treatment for hospitalized patients with COVID-19
On Apr. 7, 2020, Karyopharm Therapeutics announced plans to initiate a global randomized clinical trial for low dose…
Mesa Biotech to ship 10,000 Accula SARS-CoV-2 tests for 30 minute rapid molecular point of care diagnosis
On Apr. 7, 2020, Mesa Biotech announced it was shipping 10,000 of its Accula SARS-CoV-2 molecular rapid point…
FDA approved Emory University human clinical trials for Emory COVID-19 antiviral
On Apr. 7, 2020, the U.S. Food and Drug Administration (FDA) approved an Investigational New Drug application by…
Seattle area philanthropists responded to COVID-19 care and research needs
On Apr. 7, 2020, the University of Washington Medicine (UW) announced that more than $20 million has been…
Alzheimer’s trial screening data links high amyloid levels with early stage disease
On Apr. 6, 2020, the first published data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study…
Redhill Biopharma announced first Covid-19 patient treated with Opaganib in Israel under Compassionate Use
On Apr. 6, 2020, RedHill Biopharma announced the first patient with confirmed coronavirus (COVID-19) diagnosis had been dosed…
RedHill Biopharma announced approval of Compassionate Use of Opaganib for COVID-19 in Italy
On Apr. 6, 2020, RedHill Biopharma announced it has received authorization from the Italian National Institute for Infectious…
GSK and Vir Biotechnology entered collaboration to find coronavirus solutions
On Apr. 6, 2020, GSK and Vir Biotechnology announced a binding agreement to enter into a collaboration to…
Mateon achieved milestone in development of OT-101, a phase 3 clinical drug candidate, against COVID-19
On Apr. 6, 2020, Mateon Therapeutics announced an update on its rapid antiviral response program targeting coronaviruses, initially…
AIM ImmunoTech announced NCI award of $14.54 million to study Ampligen as part of five Roswell Park-led chemokine modulation clinical trials in melanoma, colorectal and ovarian cancers
On Apr. 6, 2020, the National Cancer Institute awarded of $14.54 million to Roswell Park Comprehensive Cancer Center…
OraSure Technologies received BARDA contract for Rapid Oral Fluid Pan-SARS-Coronavirus in-home self-test
On Apr. 6, 2020, OraSure Technologies announced it had been awarded a $710,310 contract from the Biomedical Advanced…
Luminex received FDA Emergency Use Authorization for ARIES SARS-CoV-2 assay to detect virus responsible for COVID-19 disease
On Apr. 6, 2020, Luminex announced announced that the FDA has issued an Emergency Use Authorization for its…
Minneapolis Heart Institute Foundation engaged in COVID-19 STEMI research study
On Apr. 6, 2020, the Minneapolis Heart Institute Foundation (MHIF) announced it was serving as the international coordinating…
New IHME COVID-19 forecasts find lower hospital bed need, epidemics starting to peak confirms social distancing works
On Apr. 5, 2020, updated COVID-19 estimates from the Institute for Health Metrics and Evaluation (IHME) found that…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza | Non-Profit Research | Therapeutics
Mesa Biotech to develop molecular point-of-care diagnostic test for novel Coronavirus (COVID-19)
On Apr. 4, 2020, Mesa Biotech announced the addition of the novel coronavirus (SARS-CoV-2) to its active influenza…
Mayo Clinic named national site for Convalescent Plasma Expanded Access Program
On Apr. 3, 2020, the FDA announced that the Mayo Clinic Mayo Clinic will be the lead institution…
OHSU launched in-house COVID-19 testing lab
On Apr. 3, 2020, Oregon Health & Science University (OHSU) announced that it had established an in-house COVID-19…
Mary and Ryan Finley donated $3 million to Legacy Health, OHSU to combat COVID-19
On Apr. 3, 2020, Oregon Health & Science University (OHSU) announced that Mary and Ryan Finley, moved by…
Penn Medicine launched trial to evaluate hydroxychloroquine to treat, prevent COVID-19
On Apr. 3, 2020, a trial led by the Perelman School of Medicine at the University of Pennsylvania…
The FDA announced publication of ARGOS SARS-CoV-2 reference grade sequence data
On Apr. 2, 2020, the FDAﾗin collaboration with the CDC, the Biodefense and Emerging Infections Research Resources Repository…
Novartis announced plan to initiate clinical study of Jakavi in severe COVID-19 patients and establish international compassionate use program
On Apr. 2, 2020, Novartis announced plans to initiate a phase III clinical trial in collaboration with Incyte…
Trial drug significantly blocked early stages of COVID-19 in engineered human tissues
On Apr. 2, 2020, an international team led by University of British Columbia (UBC) researcher Dr. Josef Penninger…
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors of COVID-19
On Apr. 2, 2020, Vir Biotech and Alnylam Pharma announced an expansion to their broad multi-target existing collaboration…
Cerus announced inclusion of pathogen reduction technology in ISBT recommendations for preparation of COVID-19 convalescent plasma
On Apr. 2, 2020, Cerus announced that the International Society of Blood Transfusion (ISBT) Working Party on Global…
Biotechnology | COVID-19 | FDA | Therapeutics
Incyte initiated phase 3 clinical trial of Ruxolitinib (Jakafi) as treatment for patients with COVID-19 cytokine storm
On Apr. 2, 2020, Incyte announced it was working with the U.S. Food and Drug Administration (FDA) to…
Emergent BioSolutions partnered with U.S. Government to expedite development of plasma-derived therapy for COVID-19
On Apr. 2, 2020, Emergent BioSolutions announced it had entered into a formal partnership with the U.S. government…
Fred Hutch team launched hunt for coronavirus antibodies
On Apr. 2, 2020, a team of scientists at Fred Hutchinson Cancer Research Center in Seattle began searching…